Bio-Techne Corporation (TECH) and Audentes Therapeutics Inc. (NASDAQ:BOLD) Comparison side by side

Bio-Techne Corporation (NASDAQ:TECH) and Audentes Therapeutics Inc. (NASDAQ:BOLD), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation of the two firms.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bio-Techne Corporation 681.71M 10.84 96.31M 2.51 77.70
Audentes Therapeutics Inc. N/A 0.00 128.82M -2.72 0.00

Table 1 demonstrates Bio-Techne Corporation and Audentes Therapeutics Inc.’s top-line revenue, earnings per share (EPS) and valuation.


Table 2 provides the return on assets, return on equity and net margins of the two firms.

Net Margins Return on Equity Return on Assets
Bio-Techne Corporation 14.13% 8.9% 5.6%
Audentes Therapeutics Inc. 0.00% -36.6% -33.9%


4.3 and 3.3 are the respective Current Ratio and a Quick Ratio of Bio-Techne Corporation. Its rival Audentes Therapeutics Inc.’s Current and Quick Ratios are 14.8 and 14.8 respectively. Audentes Therapeutics Inc. has a better chance of clearing its pay short and long-term debts than Bio-Techne Corporation.


Bio-Techne Corporation pays out a $1.28 per share dividend on a yearly basis and it also offers 0.66% dividend yield. Audentes Therapeutics Inc. does not pay a dividend.

Analyst Ratings

The following table given below contains the ratings and recommendations for Bio-Techne Corporation and Audentes Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Bio-Techne Corporation 0 2 2 2.50
Audentes Therapeutics Inc. 0 0 0 0.00

The downside potential is -3.65% for Bio-Techne Corporation with average price target of $188.5.

Institutional & Insider Ownership

Institutional investors owned 95.7% of Bio-Techne Corporation shares and 0% of Audentes Therapeutics Inc. shares. Insiders owned 0.1% of Bio-Techne Corporation shares. Competitively, insiders own roughly 1.3% of Audentes Therapeutics Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Bio-Techne Corporation 0.1% 11.87% 19.62% 1.8% 38.59% 34.86%
Audentes Therapeutics Inc. 18.9% 40.28% 43.46% -2.66% 2.02% 63.18%

For the past year Bio-Techne Corporation was less bullish than Audentes Therapeutics Inc.


Bio-Techne Corporation beats on 10 of the 12 factors Audentes Therapeutics Inc.

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates through three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets. It also provides various products, which serves as predictive biomarkers and therapeutic targets for various human diseases and conditions, including cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. The Protein Platforms segment develops, manufactures, and sells tools, such as Biologics platform that enables researchers interrogate protein purity and identify contaminants during the development and production of biologics; Simple Western platform for protein analysis and identification; SimplePlex platform, an enzyme-linked immunosorbent assay for use in research and clinical diagnostics; and Single Cell Western platform to elucidate the properties of individual cells to understand cell behavior. The Diagnostics segment offers controls and calibrators for hematology clinical instruments; blood chemistry and blood gas quality controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market; bulk purified proteins, enzymes, disease-state plasmas, infectious disease antigens, and processed serums to the clinical diagnostic industry; and Paratest, a novel and convenient stool collection and test device for the veterinary market. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Audentes Therapeutics, Inc., a biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects in the United States. The company is developing AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT982 for the treatment of pompe disease; and AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. Audentes Therapeutics, Inc. has a collaboration with the University of Pennsylvania for the treatment of Crigler-Najjar. The company was founded in 2012 and is headquartered in San Francisco, California.